NovaBridge Biosciences (NBP) Accumulated Expenses (2021 - 2025)

NovaBridge Biosciences (NBP) has reported Accumulated Expenses for 5 consecutive years, with $2.8 million the latest figure, recorded in Q4 2025.

• Quarterly Accumulated Expenses rose 5.71% year-over-year to $2.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.8 million (up 5.71% YoY) and the FY2025 annual result came in at $2.8 million, up 5.71% from the prior year.
• Accumulated Expenses advanced to $2.8 million in Q4 2025 per NBP's latest filing, from $1.8 million in the prior quarter.
• Over the last five years, Accumulated Expenses for NBP reached as high as $8.2 million in Q4 2021 and fell as low as $1.3 million in Q2 2025.
• A 5-year average of $4.2 million and a median of $3.4 million in 2022 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2023 — Accumulated Expenses rose 10.41% — and 2024, when it slumped 61.07%.
• Year by year, Accumulated Expenses stood at $8.2 million in 2021, then slipped by 25.58% to $6.1 million in 2022, then climbed by 10.41% to $6.8 million in 2023, then sank by 61.07% to $2.6 million in 2024, then increased by 5.71% to $2.8 million in 2025.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $2.8 million, $1.8 million, and $1.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.